Clay B. Siegall is Chief Executive Officer,President, and chairman of the board at Seattle genetics. His scientific training has focused on cancer therapies and he has played a major role in the cancer research community. Over years of practice he has spread his love and passion for helping patience, which is his main priority. He has made Seattle Genetics a top competitor in the development of antibody drug conjugates (ADCs). In 2011 they received their first FDA approval of and antibody drug conjugate. The name of their first drug is ADCETRIS® or generically brentuximab vedotin. Clay Siegall displays superb leadership as he has drove Seattle Genetics to enter into multiple strategic licenses for ADC technology. Media outlet Xconomy has featured Siegall, according to their website Siegall has secured more than 330 million dollars through capital raising activities. Siegall has formed many relationships with major companies to help develop ADCs. These companies include Genentech, MedImmune, CuraGen, Bayer and Progenics. Much of this wouldn’t have happened if not for Clay Siegall’s earlier experiences. He was with the Bristol-Myers Squibb Pharmaceutical Research Institute where he gained a foundation. Prior to that even he went to George Washington University where he gained his Ph.D. The over achieving man has also received many prestigious rewards. The 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences being one of them. The biggest goal of all are the many lives saved from the anti-body conjugates and the plus that they only attack the right cells and not all cells like chemotherapy does. All of this is being greatly forwarded by Clay Siegall, a professional life saver.